Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 516Bevacizumab 487Carboplatin 424pembrolizumab 384Paclitaxel 384Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 295Nivolumab 247Doxorubicin 243Dexamethasone 239Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 200Etoposide 187Cetuximab 184Lenalidomide 176Pemetrexed 175Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 165Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × titanium silicide × Clear all
NCT03382600 2024-06-11

KEYNOTE-659

Merck Sharp & Dohme LLC

Phase 2 Completed
100 enrolled 21 charts
Gastrointestinal

Stomach Neoplasms

NCT00429858 2020-09-18

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 2 Terminated
21 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00438100 2015-05-29

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Japan Breast Cancer Research Network

Phase 2 Completed
142 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡